Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works

Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · see citing works

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733 · see citing works

Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403 · see citing works

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,319 · see citing works

Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater

Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670 · see citing works

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662 · see citing works

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260 · see citing works

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Gadgeel, S. M., Rodríguez‐Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P. R., Powell, S. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03136 · Cited by 1,118 · see citing works

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez‐Abreu, D., Moro‐Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 953 · see citing works

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841 · see citing works

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Shen, G., Zheng, F., Ren, D., Du, F., Dong, Q., Wang, Z., Zhao, F., Ahmad, R., & Zhao, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0664-7 · Cited by 665 · see citing works

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 661 · see citing works

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Han, B., Li, K., Wang, Q., Zhang, L., Shi, J., Wang, Z., Cheng, Y., He, J., Shi, Y., Zhao, Y., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3039 · Cited by 617 · see citing works

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

Goldberg, S. B., Schalper, K. A., Gettinger, S. N., Mahajan, A. K., Herbst, R. S., Chiang, A. C., Lilenbaum, R., Wilson, F. H., Omay, S. B., Yu, J. B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30111-x · Cited by 539 · see citing works

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer

Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02627 · Cited by 522 · see citing works

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30020-8 · Cited by 476 · see citing works

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Gao, S., Li, N., Gao, S., Xue, Q., Ying, J., Wang, S., Tao, X., Zhao, J., Mao, Y., Wang, B., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.017 · Cited by 401 · see citing works

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yang, Y., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., Ma, R., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.07.014 · Cited by 390 · see citing works

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

Taylor, M., Lee, C.-H., Makker, V., Rasco, D., Dutcus, C., Wu, J., Stepan, D., Shumaker, R., & Motzer, R. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01598 · Cited by 327 · see citing works

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Herbst, R. S., Arkenau, H., Santana-Dávila, R., Calvo, E., Paz-Ares, L. G., Cassier, P. A., Bendell, J. C., Penel, N., Krebs, M., Martín-Liberal, J., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30458-9 · Cited by 269 · see citing works

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Han, B., Li, K., Zhao, Y., Li, B., Cheng, Y., Zhou, J., Lü, Y., Shi, Y., Wang, Z., Jiang, L., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.478 · Cited by 260 · see citing works

Sintilimab: First Global Approval

Hoy, S. M. (2019) · Drugs · doi:10.1007/s40265-019-1066-z · Cited by 207 · see citing works

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Cremolini, C., Loupakis, F., Antoniotti, C., Lonardi, S., Masi, G., Salvatore, L., Cortesi, E., Tomasello, G., Spadi, R., Zaniboni, A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv112 · Cited by 192 · see citing works

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells

Liu, S., Qin, T., Liu, Z., Wang, J., Jia, Y., Feng, Y., Gao, Y., & Li, K. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2511-3 · Cited by 192 · see citing works

Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer

Crabb, S. J., Patsios, D., Sauerbrei, E. E., Ellis, P. M., Arnold, A., Goss, G. D., Leighl, N. B., Shepherd, F. A., Powers, J., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2545 · Cited by 159 · see citing works

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

Wang, J., Fei, K., Hua, J., Wu, Z., Wu, W., Zhou, S., Ni, H., Chen, B., Xiong, Y., Liu, Y., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1654303 · Cited by 148 · see citing works

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy

McCoach, C. E., Blumenthal, G. M., Zhang, L., Myers, A. P., Tang, S. W., Sridhara, R., Keegan, P., Pazdur, R., Doebele, R. C., & Kazandjian, D. G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx414 · Cited by 98 · see citing works

A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results

Llovet, J. M., Shepard, K., Finn, R., Ikeda, M., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz247.073 · Cited by 67 · see citing works

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma

Grünwald, V., Lin, X., Kalanovic, D., & Simantov, R. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.010 · Cited by 26 · see citing works

Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib

Chen, D., Xu, J., Zhao, Y., Chu, T., Zhong, H., Han, B., & Zhong, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03064-1 · Cited by 26 · see citing works

Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin

Nishina, T., Azuma, M., Nishikawa, K., Gotoh, M., Bando, H., Sugimoto, N., Amagai, K., Chìn, K., Niwa, Y., Tsuji, A., et al. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0845-7 · Cited by 21 · see citing works

Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study

Vivaldi, C., Fornaro, L., Cappelli, C., Pecora, I., Catanese, S., Salani, F., Insilla, A. C., Kauffmann, E. F., Donati, F., Pasquini, G., et al. (2019) · Cancers · doi:10.3390/cancers11070939 · Cited by 21 · see citing works

Influence and mechanism of lung cavitation development on antiangiogenic therapy

Jiang, M., Zhang, C., Liu, D., Wang, Y., Wang, H., Li, T., Hou, H., Zhou, N., Zhu, J., Lv, H., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.07.01 · Cited by 18 · see citing works

Phase Ib study of sintilimab in combination with chemotherapy for 1L advanced or metastatic non-small cell lung cancer (NSCLC).

Xu, N., Ying, K., Wang, Z., Liu, Y., Jiang, H., Zhou, H., & Wang, S. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e20546 · Cited by 10 · see citing works

MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF)

Herbst, R. S., Arkenau, H., Bendell, J. C., Arrowsmith, E. R., Wermke, M., Soriano, À., Penel, N., Santana-Dávila, R., Bischoff, H., Chau, I., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.615 · Cited by 4 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Non‐small cell lung cancer in China

Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · 癌症：英文版 · doi:10.1002/cac2.12359 · Cited by 673 · see citing works

Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance

Wang, S., Wang, J., Chen, Z., Luo, J., Guo, W., Sun, L., & Lin, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00522-z · Cited by 600 · see citing works

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons

Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L. P., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 526 · see citing works

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 278 · see citing works

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11030320 · Cited by 263 · see citing works

New clinical trial design in precision medicine: discovery, development and direction

Duan, X.-P., Qin, B., Jiao, X., Liu, K., Wang, Z., & Zang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 217 · see citing works

Advances in molecular pathology and therapy of non-small cell lung cancer

Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197 · see citing works

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial

Xu, Q., Wang, J., Sun, Y., Lin, Y., Liu, J., Zhuo, Y., Huang, Z., Huang, S., Chen, Y., Chen, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02091 · Cited by 154 · see citing works

Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma

Su, Y., Luo, B., Lu, Y., Wang, D., Yan, J. Y., Zheng, J., Xiao, J. H., Wang, Y., Xue, Z., Yin, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2241 · Cited by 147 · see citing works

Novel strategies for cancer immunotherapy: counter-immunoediting therapy

Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 98 · see citing works

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis

Lei, T., Xu, T., Zhang, N., Zou, X., Kong, Z., Wei, C., & Wang, Z. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106668 · Cited by 66 · see citing works

Emerging biomaterials for tumor immunotherapy

Xiao, M., Tang, Q., Zeng, S., Yang, Q., Yang, X., Tong, X., Zhu, G., Lei, L., & Li, S. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00369-8 · Cited by 64 · see citing works

Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents

Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 54 · see citing works

Anlotinib potentiates anti‐PD1 immunotherapy via transferrin receptor‐dependent CD8 + T‐cell infiltration in hepatocellular carcinoma

Song, F., Hu, B., Liang, X., Cheng, J., Wang, C., Wang, P., Wang, T., Tang, P., Sun, H., Guo, W., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1738 · Cited by 55 · see citing works

Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities

Wang, H., Niu, X., Jin, Z., Zhang, S., Fan, R., Xiao, H., & Hu, S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03519-z · Cited by 59 · see citing works

Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer

de Jong, D., Das, J. P., Ma, H., Valiplackal, J. P., Prendergast, C. M., Roa, T., Braumuller, B., Deng, A., Dercle, L., Yeh, R., et al. (2023) · Cancers · doi:10.3390/cancers15102855 · Cited by 52 · see citing works

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Zhou, J., Sun, Y., Zhang, W., Yuan, J., Peng, Z., Wang, W., Gong, J., Yang, L., Cao, Y., Zhao, H., et al. (2022) · Hepatology · doi:10.1002/hep.32548 · Cited by 51 · see citing works

A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer

Chen, B., Yao, W., Li, X., Lin, G., Chu, Q., Liu, H., Du, Y., Lin, J., Duan, H., Wang, H., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02519-0 · Cited by 43 · see citing works

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study

Chen, X., Li, W., Wu, X., Zhao, F., Wang, D., Wu, H., Gu, Y., Li, X., Qian, X., Hu, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.909035 · Cited by 43 · see citing works

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer

Wei, W., Ban, X., Yang, F., Li, J., Cheng, X., Zhang, R., Huang, X., Huang, Y., Li, Q., Qiu, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004338 · Cited by 40 · see citing works

Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer

Choi, S. H., Yoo, S. S., Lee, S. Y., & Park, J. Y. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01382-6 · Cited by 40 · see citing works

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial

Zhou, H., Zhang, Y., Chen, G., Yu, Q.-T., Zhang, H., Wu, G., Wu, D., Lin, Y., Zhu, J., Chen, J., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01927-9 · Cited by 38 · see citing works

Sintilimab for the treatment of non-small cell lung cancer

Zhang, L., Lin, W., Tan, F., Li, N., Xue, Q., Gao, S., Gao, Y., & He, J. (2022) · Biomarker Research · doi:10.1186/s40364-022-00363-7 · Cited by 35 · see citing works

Efficacy and safety of anlotinib combined with PD ‐1/ PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer

Yu, L., Xu, J., Qiao, R., Han, B., Zhong, H., & Zhong, R. (2022) · Cancer Medicine · doi:10.1002/cam4.5360 · Cited by 34 · see citing works

Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial

Jin, S., Zhao, R., Zhou, C., Zhong, Q., Shi, J., Su, C., Li, Q., Su, X., Chi, H., Lu, X., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34372 · Cited by 32 · see citing works

Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy

Zhang, M., Wei, Z., Wei, B., Lai, C., Zong, G., Tao, E., Fan, M., Pan, Y., Zhou, B., Shen, L., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.04.022 · Cited by 31 · see citing works

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer

Xiong, Q., Qin, B., Xin, L., Yang, B. Y., Song, Q., Wang, Y., Zhang, S., & Hu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659380 · Cited by 33 · see citing works

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

Zeng, Z., Qian, X., Liu, F., Wang, Y., Yuan, Y., Chen, F., Zhang, X., Yuan, S., Chen, R., Yu, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956982 · Cited by 31 · see citing works

Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial

Han, X., Guo, J., Li, L., Huang, Y., Meng, X., Wang, L., Zhu, H., Meng, X., Shao, Q., Li, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01957-3 · Cited by 30 · see citing works

A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world

Shi, Y. X., Ji, M., Jiang, Y., Yin, R. L., Wang, Z., Li, H., Wang, S., He, K., Ma, Y., Wang, Z., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-350 · Cited by 30 · see citing works

A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first‐line therapy in patients with newly diagnosed, stage I–II extranodal natural‐killer/T‐cell lymphoma

Sun, P., Li, Y., Li, C., Ren, K., Wang, Y., Yang, H., Jiang, W., Zou, L., Yang, H., Zhou, H., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26922 · Cited by 26 · see citing works

Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors

Zhou, Y. J., Liu, Z., Yu, A., Zhao, G., & Chen, B. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s494670 · Cited by 26 · see citing works

Multi‐target angiogenesis inhibitor combined with PD ‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy

Yu, L., Hu, Y., Xu, J., Qiao, R., Zhong, H., Han, B., Xia, J., & Zhong, R. (2023) · International Journal of Cancer · doi:10.1002/ijc.34536 · Cited by 26 · see citing works

Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma

Tang, H. J., You, T., Ge, H., Gao, J., Wang, Y., Bai, C., Sun, Z., Han, Q., & Zhao, R. C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112053 · Cited by 25 · see citing works

Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial

Ma, S., He, Z., Liu, Y., Wang, L., Yang, S., Wu, Y., Chen, H., Wu, Y., & Wang, Q. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102543 · Cited by 25 · see citing works

Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs

Dong, S., Li, X., Huang, Q., Li, Y., Li, J., Zhu, X., Xue, C., Chen, R., Zeng, Y., Wu, J., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101215 · Cited by 24 · see citing works

Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

Ren, S., He, J., Fang, Y., Chen, G., Ma, Z., Chen, J., Guo, R., Lin, X., Yao, Y., Wu, G., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100312 · Cited by 24 · see citing works

Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer

Fang, L., Zhao, W., Ye, B., & Chen, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670313 · Cited by 23 · see citing works

Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy

Kiasari, B. A., Abbasi, A., Darestani, N. G., Adabi, N., Moradian, A., Yazdani, Y., Hosseini, G. S., Gholami, N., & Janati, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109365 · Cited by 25 · see citing works

Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy

Sereno, M., de Córdoba, I. H., Gutiérrez‐Gutiérrez, G., & Casado, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1297988 · Cited by 23 · see citing works

Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review

Wu, S., Wu, S., Liao, X., Zhou, C., Qiu, F. X., Wang, C., & Zhong, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1274937 · Cited by 22 · see citing works

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives

Zhao, Y., Liu, L., & Weng, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.714483 · Cited by 23 · see citing works

Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway

Han, X., Liu, J., Zhang, Y., Tse, E., Yu, Q., Yu, L., Ma, Y., & Zheng, L. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.100984 · Cited by 21 · see citing works

Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis

Lin, Y., Gao, H., Yang, X., Zhu, T., Zheng, X., Ji, F., Zhang, L., Yang, C.-Q., Yang, M., Li, J., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.08.006 · Cited by 22 · see citing works

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer

He, D.-M., Wang, L., Xu, J.-C., Zhao, J., Bai, H., & Wang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1265865 · Cited by 21 · see citing works

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC

Wang, S., Lou, N., Luo, R., Hao, X., Liu, Y., Wang, L., Shi, Y., & Han, X. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03451-2 · Cited by 20 · see citing works

Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients

Yuan, S., Peng, L., Liu, Y., Till, B. G., Yan, X., Zhang, J., Zhu, L., Wang, H., Zhang, S., Li, H., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03259-5 · Cited by 20 · see citing works

Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials

Li, L., Wen, Q., & Ding, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.905520 · Cited by 19 · see citing works

Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study

Chu, T., Zhang, W., Zhang, B., Zhong, R., Zhang, X., Gu, A., Shi, C., Wang, H., Xiong, L., Lü, J., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-438 · Cited by 19 · see citing works

The war between the immune system and the tumor - using immune biomarkers as tracers

Yang, K., Lu, R., Mei, J., Cao, K., Zeng, T., Hua, Y., Huang, X., Li, W., & Yin, Y. (2024) · Biomarker Research · doi:10.1186/s40364-024-00599-5 · Cited by 19 · see citing works

Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)

Duan, H., Shao, C., Luo, Z., Wang, T., Tong, L., Liu, H., Yao, X., Lei, J., Zhao, J., Gao, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01992-0 · Cited by 19 · see citing works

Synergizing Success: The Role of Anlotinib Combinations in Advanced Non-Small Cell Lung Cancer Treatment

Hetta, ‏. F., Aljohani, H. M., Sirag, N., Elfadil, H., Salama, A., Al-Twalhy, R., Alanazi, D. A., Aljohani, M. M., Albalawi, J. H., Al-Otaibi, R. M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18040585 · Cited by 19 · see citing works

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer

Mussafi, O., Mei, J., Mao, W., & Wan, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.948405 · Cited by 18 · see citing works

Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies

Gao, R.-L., Song, J., Sun, L., Wu, Z.-X., Yi, X.-F., Zhang, S., Huang, L., Ma, J., & Han, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.920165 · Cited by 17 · see citing works

Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study

Dou, X.-J., Ma, R.-Y., Ren, D.-W., Liu, Q., & Yan, P. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s444884 · Cited by 17 · see citing works

Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL)

Zhang, Y., Zou, Q., Zhao, B., Su, N., Li, Z., Wang, X., Liu, P., Tian, X., Fang, X., Cai, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101833 · Cited by 17 · see citing works

Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma

Ma, W., Liang, J., Mo, J., Zhang, S., Hu, N., Tian, D., & Chen, Z. (2021) · BMC Cancer · doi:10.1186/s12885-021-08790-9 · Cited by 16 · see citing works

Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers

Shi, Y., Li, Y., Wu, B., Zhong, C., Lang, Q., Liang, Z., Zhang, Y., Lv, C., Han, S., Yu, Y., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108968 · Cited by 17 · see citing works

Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study

Yu, L., Xu, J., Qiao, R., Zhong, H., Brueckl, W. M., & Zhong, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-260 · Cited by 15 · see citing works

A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer

Zhang, W. J., Wang, J., Wang, Q., Cheng, Y., Yang, L., Li, Y., Zhong, H., Chu, T., Dong, Y., Zhang, Y., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107353 · Cited by 15 · see citing works

Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases

Yang, G., Xing, L., & Sun, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.852811 · Cited by 15 · see citing works

Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study

Wang, W., Shao, L., Xu, Y., Song, Z., Lou, G., Zhang, Y., & Chen, M. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-01981-5 · Cited by 15 · see citing works

Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients

Feng, Y., Tang, L. M., Wang, H., Liu, Y., Yang, S., Lin, L., Hu, X., & Shi, Y. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03251-z · Cited by 14 · see citing works

Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer

Li, L., Pu, H., Zhang, X., Guo, X., Li, G., & Zhang, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104683 · Cited by 14 · see citing works

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer

Wang, F., Jin, F., Cheng, B., Zhang, Y., Zhou, Q. H., & Wang, S. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03752-x · Cited by 14 · see citing works

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma

Sun, P., Wang, Y., Yang, H., Chen, C., Nie, M., Sun, X., He, X., Huang, K.-M., Huang, J., & Li, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.766200 · Cited by 14 · see citing works

Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy

To, K. K. W., & Cho, W. C. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082166 · Cited by 13 · see citing works

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study

Liu, Y., Ge, Q., Xu, S., Li, K., & Liu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942678 · Cited by 13 · see citing works

Anlotinib reduces the suppressive capacity of monocytic myeloid-derived suppressor cells and potentiates the immune microenvironment normalization window in a mouse lung cancer model

Zhao, X., Zhao, R., Wen, J., Zhang, X., Wu, S., Fang, J., Ma, J., Zheng, W., Zhang, X., Lu, Z., et al. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001481 · Cited by 13 · see citing works

Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer

Lv, W., Pei, X., Zhao, W., Cong, Y., Wei, Y., Li, T., Zhang, H., Zhong, L., Saito, Y., Kim, J. J., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-49 · Cited by 12 · see citing works

Pan‐cancer efficacy and safety of anlotinib plus PD ‐1 inhibitor in refractory solid tumor: A single‐arm, open‐label, phase II trial

Qin, B., Jiao, X., Wang, Z., Liu, K., Wu, Y., Ling, Y., Chen, S., Zhong, X., Duan, X., Qin, W., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34546 · Cited by 12 · see citing works

Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

Chen, K., Xu, Y., Huang, Z., Yu, X., Hong, W., Li, H., Xu, X., Lu, H., Xie, F., Chen, J., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6548 · Cited by 12 · see citing works

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial

Ren, S., Wang, X., Han, B., Pan, Y., Zhao, J., Cheng, Y., Hu, S., Liu, T., Li, Y., Cheng, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007227 · Cited by 12 · see citing works

Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study

Shi, M., Chen, P., Cui, B., Yao, Y., Wang, J., Zhou, T., & Wang, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01982-2 · Cited by 12 · see citing works

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC

Huang, H., Zhong, P., Zhu, X., Fu, S., Li, S., Peng, S., Liu, Y., Lu, Z., & Chen, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1137224 · Cited by 12 · see citing works

Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study

Ma, K., Guo, Q., & Li, X. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02470-z · Cited by 12 · see citing works

Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial

Meng, X., Yang, X., Hong, Y., Wang, W., Zhang, Z., Xia, J., Chen, Y., Zhou, Y., Lu, T., Song, M. S., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02376-w · Cited by 11 · see citing works

Neoadjuvant anlotinib/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): Phase 2 trial

Zhang, L., Yang, L., Ge, Y., Zhu, Z., Chen, B., Yang, C., Gao, H., Yang, M., Zhu, T., & Wang, K. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102193 · Cited by 11 · see citing works

Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial

Chu, T., Zhong, H., Yu, Z., Wang, J., Zhao, Y., Mu, X., Yu, X., Shi, X., Shi, Q., Guan, M., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.12654 · Cited by 11 · see citing works

Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer

D’Aiello, A., Miao, E., & Cheng, H. (2023) · Cancers · doi:10.3390/cancers15030844 · Cited by 11 · see citing works

Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues

Schirizzi, A., Leonardis, G. D., Lorusso, V., Donghia, R., Rizzo, A., Vallarelli, S., Ostuni, C., Troiani, L., Lolli, I. R., Giannelli, G., et al. (2023) · Cancers · doi:10.3390/cancers15082376 · Cited by 11 · see citing works

Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study

Jiang, J., Wu, B., Sun, Y., Xiang, J., Shen, C., He, X., Ying, H., & Xia, Z. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03784-5 · Cited by 10 · see citing works

Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial

Shen, Y., Lü, J., Hu, F., Qian, J., Zhang, X., Zhong, R., Zhong, H., Chu, T., & Han, B. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03964-9 · Cited by 10 · see citing works

Current status and future of anti-angiogenic drugs in lung cancer

Yan, X., Zhao, Z., & Tang, H. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01039-8 · Cited by 10 · see citing works

Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances

Dehghani, T., Shahrjerdi, A., Kahrizi, M. S., Soleimani, E., Ravandeh, S., Merza, M. S., Rahnama, N., Ebrahimzadeh, F., & Bakhshesh, M. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154470 · Cited by 10 · see citing works

Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer

Zhou, J., Chen, G., Wang, J., Zhou, B., Sun, X., Wang, J., Tang, S., Xing, X., Hu, X., Zhao, Y., et al. (2023) · Oncogenesis · doi:10.1038/s41389-023-00468-0 · Cited by 10 · see citing works

Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell Lung Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report

Luo, Z., Zhang, H., Xiao, Y., Wang, R., Zhang, L., Huang, C., Cao, Y. Q., Sun, C., Zhao, Y., Lin, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633446 · Cited by 10 · see citing works

Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer

Cheng, Y., Li, H., Zhang, L., Liu, J., Yang, C., & Zhang, S. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001560 · Cited by 10 · see citing works

Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study

Pu, X., Lin, G., Xiao, M., Lin, J., Wang, Q., Kong, Y., Yan, X., Xu, F., Xu, Y., Li, J., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102403 · Cited by 9 · see citing works

Landscape of the clinical development of China innovative anti-lung cancer drugs

Shi, Y. (2022) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2022.10.003 · Cited by 9 · see citing works

Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study

Hong, Y., Liu, J., Lu, P., Zhi-wei, C., Zhang, G., Ma, X., Wei, L., Tian, Y., Xia, J., Cao, H., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae245 · Cited by 9 · see citing works

Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review

Piao, M., Ma, X., Tankéré, P., Liam, C. K., Li, J., & Wang, J. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-4312 · Cited by 9 · see citing works

A novel prediction model for the prognosis of non-small cell lung cancer with clinical routine laboratory indicators: a machine learning approach

Wang, Y., Mei, N., Zhou, Z., Fang, Y., Lin, J., Zhao, F., Fang, Z., & Yan, L. (2024) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-024-02753-3 · Cited by 8 · see citing works

Sintilimab Plus Axitinib for Advanced Fumarate Hydratase–Deficient Renal Cell Carcinoma

Zhang, X., Liu, H., Liang, J., Zhao, J., Wang, Y., Chen, Y., Kang, D., Chen, Q., Zhang, Y., Yin, X., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.2497 · Cited by 9 · see citing works

Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review

Liu, Z., Yu, M., Zhao, F. H., & Zhu, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.976415 · Cited by 8 · see citing works

Comparison of cardiotoxicity induced by alectinib, apatinib, lenvatinib and anlotinib in zebrafish embryos

Liu, J., Li, W., Sun, S., Huang, L., Wan, M., Li, X., Zhang, L., Yang, D., Liu, F., Liao, X., et al. (2024) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2024.109834 · Cited by 8 · see citing works

Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Yang, M., Cao, H., Wang, C., Yu, C., & Sun, P. (2024) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1031_23 · Cited by 9 · see citing works

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study

Li, X.-Y., Rao, Y., Sun, B., & Mao, X.-M. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s352536 · Cited by 8 · see citing works

Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy

Zhang, T., Zhang, C., Fu, Z., & Gao, Q. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091768 · Cited by 8 · see citing works

P1.04-02 Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

Han, B., Chu, T., Zhong, R., Zhong, H., Zhang, B., Zhang, W., Shi, C., Qian, J., & Han, Y. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.905 · Cited by 15 · see citing works

OA07.09 Sintilimab in Combination with Anlotinib as First-Line Therapy for Advanced NSCLC: Final Analysis of Primary Endpoints

Han, B., Chu, T., Zhong, R., Zhong, H., Zhang, B., Zhang, W., Shi, C., Qian, J., Zhang, Y., Chang, Q., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.300 · Cited by 2 · see citing works

JCSE01.11 Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

Han, B., Chu, T., Zhong, R., Zhong, H., Zhang, B., Zhang, W., Shi, C., Qian, J., & Han, Y. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.269 · Cited by 15 · see citing works

497P Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial

Jin, Y., Yu, X., Fan, Y., X., He, Q., Lin, C., Hong, W., & Gu, C. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.572

An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD ‐(L)1 Inhibitor

Shi, X., Chen, L., Lou, L., He, Q., Lou, G., Hong, W., Shao, L., Zhao, J., Gu, C., Yu, X., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71191 · Cited by 3 · see citing works